CTOs on the Move

Womens International Pharmacy

www.womensinternational.com

 
It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Vista Pharmaceuticals

Vista Pharmaceuticals is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Torrent Pharma Inc

Torrent Pharma Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quartesian

Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.

Concept Life Sciences

Concept Life Sciences provides integrated, high quality drug discovery, development and analytical services to the life science sector. Formed as a result of targeted acquisition and organic growth, the Company has the in-house expertise and resource to support customers with projects spanning from target discovery to the clinic, adding value and IP throughout the discovery pathway. With a track record of delivering knowledge-based, science-led solutions, the Company employs over 700 FTEs, including more than 500 highly skilled, experienced scientists, supporting its global client base from 11 state of the art laboratory facilities.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.